Skip to content

Letrozole Plus Misoprostol Versus Misoprostol Only in Induction of Missed Abortion

Letrozole Plus Misoprostol Versus Misoprostol Only in Induction of Missed Abortion: A Randomized Controlled Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07636317
Enrollment
400
Registered
2026-06-09
Start date
2025-06-14
Completion date
2026-03-01
Last updated
2026-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Induction, Letrozole, Misoprostol, Missed Abortion

Brief summary

This study aimed to evaluate the effect of letrozole plus misoprostol to terminate non-viable pregnancies in first trimester compared with the use of misoprostol alone.

Detailed description

Inducing abortion by drugs is an alternative for surgery intervention, which has economic benefits with lower side effects and its rate of success is 60 to 95%. Letrozole is also one of aromatase inhibitors, which is used to stimulate ovulation in infertile women suffering ovulatory dysfunction. This drug is one of the main drugs for inhibiting aromatase, with a relatively short 45-hour half life, which is active orally and inhibits aromatase enzyme reversibly. Misoprostol is a relatively safe drug and of its side effects it is possible to mention to gestational effects, feeling of warmth, and shivering. Severe side effects of misoprostol consumption are severe bleeding and endometritis, with less than 1% prevalence based on studies.

Interventions

DRUGLetrozole + Misoprostol

Patients received 10 mg of Letrozole daily for three days, subsequently receiving 800 µg of Misoprostol every three hours via vaginal or sublingual routes.

DRUGMisoprostol

Patients received only 800 µg of Misoprostol.

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Age from 18 to 45 years. * Women with nonviable pregnancies undergoing 1st-trimester abortion.

Exclusion criteria

* Medical diseases like renal or liver disease. * Severe bleeding and shocked patients. * Inevitable abortion. * Hypersensitivity to any of the drugs.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of bleeding7 days following the Misoprostol doseIncidence of bleeding was recorded.

Secondary

MeasureTime frameDescription
Number of dosages of prostaglandins7 days following the Misoprostol doseNumber of dosages of prostaglandins was recorded.
Duration required for abortion7 days following the Misoprostol doseDuration required for abortion was recorded.
Incidence of adverse effects7 days following the Misoprostol doseIncidence of adverse effects such as nausea, vomiting, gastric distress, headache, fever, and shivers were recorded.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 10, 2026